This warning shows up when the page has a very small width.
Development for smaller screens is underway, and only the main page is coded so far.
This does not reflect the final state of the site.

We strive to push the boundaries of medical research in our quest for innovative treatment for cancer and inflammation

We are a clinical-stage company committed to delivering transformative therapies for people battling cancer and autoimmune disease. Through our relentless pursuit of breakthroughs in immuno-oncology and inflammation research, we aim to redefine the treatment landscape.

Our diverse portfolio of immuno-modulating antibody candidates is meticulously designed to engage both the innate and adaptive immune arms, enabling us to offer unprecedented therapies. These groundbreaking approaches hold the potential to create a paradigm shift in cancer treatment, delivering profound benefits to patients and their families.

Company

Established in 2019 in Suzhou, China, and subsequently expanding to San Diego, USA, in 2021, NeoLogics Bioscience Co., Ltd is a dynamic clinical-stage biotech company driven by an unyielding commitment to revolutionize patient care. Our primary focus centers on cancer and autoimmune disease, as we passionately strive to develop and deliver innovative therapeutics that would have a positive impact on patient’s life.

Through rigorous scientific inquiry and translational research, we discover novel treatment approaches that address the complex challenges of cancer and autoimmune diseases. To ensure a sustainable and robust pipeline, we have implemented state-of-the-art methodologies within our research and development process. Our integration of cutting-edge in silico data mining, analysis, and phenotypical target validation systems allows us to optimize our approach and accelerate the discovery of novel therapies. This strategic utilization of advanced technology enables us to stay at the forefront of scientific advancements and deliver groundbreaking solutions to patients in need.

Recognizing the value of collaboration and leveraging external expertise, we have forged strong partnerships with mature contract research organizations (CRO) and contract development and manufacturing organizations (CDMO) in China. By tapping into their extensive resources and knowledge, we are able to propel our pipeline towards key milestones efficiently and effectively.

By combining our passion for innovation with a strong sense of responsibility, we are committed to making a meaningful difference in the lives of patients globally.

As we continue on our journey, NeoLogics Bioscience Co., Ltd remains steadfast in our pursuit of breakthrough treatments. With a deep sense of responsibility and a passion for innovation, we are determined to shape a brighter future for patients and contribute to the advancement of medical science.